Prime Medicine, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
T. Rowe Price Investment Management, Inc. has reduced its beneficial ownership in Prime Medicine Inc. to 3.3% of common stock.
NASDAQ
T. Rowe Price Investment Management, Inc. has reported a 5.3% beneficial ownership stake in Prime Medicine Inc. common stock.
NASDAQ
Alphabet Inc. and its affiliated investment entities have reported a combined beneficial ownership of 12.3% in Prime Medicine, Inc., totaling 16,562,498 shares.
NASDAQ
FMR LLC and Abigail P. Johnson have reduced their beneficial ownership in Prime Medicine Inc. to 3.8% of common stock.
NASDAQ
SCHEDULE 13G/A: Newpath Partners Reduces Stake in Prime Medicine to 4.7%
Newpath Partners, L.P. and its affiliated entities, including board member Thomas Cahill, have reported a beneficial ownership of 4.7% in Prime Medicine, Inc. common stock as of December 31, 2024, indicating a reduction from a previous filing.